These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27038531)

  • 21. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fine-tuning the cytotoxicity of ruthenium(II) arene compounds to enhance selectivity against breast cancers.
    Pereira SAP; Romano-deGea J; Barbosa AI; Costa Lima SA; Dyson PJ; Saraiva MLMFS
    Dalton Trans; 2023 Aug; 52(33):11679-11690. PubMed ID: 37552495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
    Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
    Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.
    Bytzek AK; Koellensperger G; Keppler BK; G Hartinger C
    J Inorg Biochem; 2016 Jul; 160():250-5. PubMed ID: 26993078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
    Ruiz J; Vicente C; de Haro C; Bautista D
    Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells.
    Graminha AE; Honorato J; Correa RS; Cominetti MR; Menezes ACS; Batista AA
    Dalton Trans; 2021 Jan; 50(1):323-335. PubMed ID: 33305766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
    Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonsteroidal Anti-inflammatory-Organometallic Anticancer Compounds.
    Păunescu E; McArthur S; Soudani M; Scopelliti R; Dyson PJ
    Inorg Chem; 2016 Feb; 55(4):1788-808. PubMed ID: 26824462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
    Ratanaphan A; Nhukeaw T; Hongthong K; Dyson PJ
    Anticancer Agents Med Chem; 2017; 17(2):212-220. PubMed ID: 27039925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)-Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells.
    Nayeem N; Yeasmin A; Cobos SN; Younes A; Hubbard K; Contel M
    ChemMedChem; 2021 Nov; 16(21):3280-3292. PubMed ID: 34329530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds.
    Hongthong K; Ratanaphan A
    Curr Cancer Drug Targets; 2016; 16(7):606-17. PubMed ID: 26845433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.
    Hiyoshi H; Goto N; Tsuchiya M; Iida K; Nakajima Y; Hirata N; Kanda Y; Nagasawa K; Yanagisawa J
    Sci Rep; 2014 Nov; 4():7095. PubMed ID: 25403352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
    Narla RK; Chen CL; Dong Y; Uckun FM
    Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity.
    Bratsos I; Urankar D; Zangrando E; Genova-Kalou P; Košmrlj J; Alessio E; Turel I
    Dalton Trans; 2011 May; 40(19):5188-99. PubMed ID: 21465046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study.
    Michlewska S; Maly M; Wójkowska D; Karolczak K; Skiba E; Hołota M; Kubczak M; Ortega P; Watala C; Javier de la Mata F; Bryszewska M; Ionov M
    Int J Pharm; 2023 Apr; 636():122784. PubMed ID: 36858135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.